Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis

Li,Dan; Qian,Wang; Li,Ruo  Ran; Zhang,Jinghao; Li,Ke; Wu,Yanmin

doi:10.3892/br.2016.619

Correlation between lung neoplasm and serum level of osteopontin: A meta-analysis

Authors:
- Dan Li
- Wang Qian
- Ruo Ran Li
- Jinghao Zhang
- Ke Li
- Yanmin Wu
View Affiliations

Affiliations: Department of Respiratory Medicine, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China, Department of Hematology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: February 29, 2016 https://doi.org/10.3892/br.2016.619
Pages: 567-572
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this meta-analysis was to evaluate the clinical significance of serum osteopontin (OPN) levels in lung neoplasm in patients to establish a novel diagnostic score model. Articles were identified by searching the PubMed, Web of Science, Google Scholar, China National Knowledge Infrastructure, and Wang Fang databases. Studies identified were pooled, and the standardized mean difference (SMD) and its corresponding 95% confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted. Version 12.0 STATA software was used for statistical analysis. A final analysis of 1,327 subjects together (740 patients with lung neoplasms and 587 controls) was performed from 10 clinical case‑control studies. The meta‑analysis results showed a positive association between serum OPN levels and lung neoplasm (SMD=5.59, 95% CI: 1.85-3.32, P<0.001). The subgroup analysis by ethnicity detected that high levels of serum OPN may be the main risk factor for lung neoplasms in Asians (SMD=1.76, 95% CI: 1.24‑2.29, P<0.001), but not in Caucasians (P=0.072). In conclusion, the present meta-analysis indicated that serum OPN levels were generally elevated in lung neoplasm patients, and thus, serum levels of OPN may be useful in diagnosing lung neoplasm in certain population groups.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J and Goldstraw P: International Staging Committee and Participating Institutions: The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
4	Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 11:4646–4652. 2005. View Article : Google Scholar : PubMed/NCBI
5	Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY, Park S and Cheon MJ: Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul). 75:104–110. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chang YS, Kim HJ, Chang J, Ahn CM and Kim SK and Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer. 57:373–380. 2007. View Article : Google Scholar : PubMed/NCBI
7	Moszynski R, Szubert S, Szpurek D, Michalak S and Sajdak S: Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res. 39:1518–1525. 2013. View Article : Google Scholar : PubMed/NCBI
8	Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC and Spencer MJ: Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 119:1583–1594. 2009. View Article : Google Scholar : PubMed/NCBI
9	Cho HJ, Cho HJ and Kim HS: Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 11:206–213. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lund SA, Giachelli CM and Scatena M: The role of osteopontin in inflammatory processes. J Cell Commun Signal. 3:311–322. 2009. View Article : Google Scholar : PubMed/NCBI
11	Okyay K, Tavil Y, Sahinarslan A, Tacoy G, Turfan M, Sen N, Gurbahar O, Boyaci B, Yalcin R, Demirkan D, et al: Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction. Acta Cardiol. 66:197–202. 2011.PubMed/NCBI
12	Song G, Ouyang G, Mao Y, Ming Y, Bao S and Hu T: Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 13(8B): 1706–1718. 2009. View Article : Google Scholar : PubMed/NCBI
13	Xu YY, Zhang YY, Lu WF, Mi YJ and Chen YQ: Prognostic value of osteopontin expression in breast cancer: A meta-analysis. Mol Clin Oncol. 3:357–362. 2015.PubMed/NCBI
14	Yuan SM, Wang J, Huang HR and Jing H: Osteopontin expression and its possible functions in the aortic disorders and coronary artery disease. Rev Bras Cir Cardiovasc. 26:173–182. 2011. View Article : Google Scholar : PubMed/NCBI
15	Wang YD, Chen H, Liu HQ and Hao M: Correlation between ovarian neoplasm and serum levels of osteopontin: A meta-analysis. Tumour Biol. 35:11799–11808. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kang CG, Han HJ, Lee HJ, Kim SH and Lee EO: Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines. Bioorg Med Chem Lett. 25:1956–1960. 2015. View Article : Google Scholar : PubMed/NCBI
17	Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT and Mælandsmo GM: Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 13:5402013. View Article : Google Scholar : PubMed/NCBI
18	Sun BS, Li Y, Zhang ZF, You J and Wang CL: Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 96:1943–1951. 2013. View Article : Google Scholar : PubMed/NCBI
19	Peng B, Wang YH, Huang Z, Feng SJ and Wang YS: Prognostic significance of osteopontin in patients with lung cancer: A meta-analysis. Int J Clin Exp Med. 7:4616–4626. 2014.PubMed/NCBI
20	Yan CH, Lv M, Li H, Song X, Yan F, Cao S and Ren X: Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection. J Cancer Res Clin Oncol. 141:1371–1378. 2015. View Article : Google Scholar : PubMed/NCBI
21	Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A and Syrigos KN: Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol. 27:332–338. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhou H, Wu T and Zhu Y: The clinical significance of serum osteopontin in diagnosis of lung cancer. J Radioimmunol. 24:458–459. 2011.(In Chinese).
23	Jackson D, White IR and Riley RD: Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 31:3805–3820. 2012. View Article : Google Scholar : PubMed/NCBI
24	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
25	Zintzaras E and Ioannidis JP: HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 21:3672–3673. 2005. View Article : Google Scholar : PubMed/NCBI
26	Song C: Clinical significance of determination of changes CEA, SA, OPN, and VEGF levels after operative in patients with lung cancer. Frontier Med. 15:75–76. 2014.
27	Qiu Y and Fu Z: Clinical significance of determination on serum levels of vascular endothelial growth factor per platelet count and osteopontin patients with locally advanced non-small cell lung cancer (unpublished PhD thesis). Hebei Medical University. Shijiazhuang: R734.2:2012.
28	Xu C, Yu K and Wang Q: The levels and clinical significance of osteopontin in serum of patients with lung cancer. J Chin Physician. 14:179–181. 2012.
29	Karadag F, Gulen ST, Karul AB, Kilicarslan N, Ceylan E, Kuman NK and Cildag O: Osteopontin as a marker of weight loss in lung cancer. Scand J Clin Lab Invest. 71:690–694. 2011. View Article : Google Scholar : PubMed/NCBI
30	Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S and Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol. 28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
31	Yin M and Zhang J: Study on OPN levels of serum in non-small cell lung cancer. Ningxia Med J. 31:679–680. 2009.
32	Dong S, Shao Z, Pan Y, Dai J and Chen G: The clinical significance of detection of serum osteopontin in patient with lung cancer. Mod J Integr Tradit Chin West Med. 17:3740–3741. 2008.
33	Weng W and Fu C: Value of serum osteopontin determination in patient with lung carcinoma. Lab Med Clin. 4:1025–1026. 2007.
34	Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 7:4060–4066. 2001.PubMed/NCBI
35	Chambers AF and Vanderhyden BC: Ovarian cancer biomarkers in urine. Clin Cancer Res. 12:323–327. 2006. View Article : Google Scholar : PubMed/NCBI
36	Lin CK, Chao TK, Lai HC and Lee HS: LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. Am J Clin Pathol. 137:971–977. 2012. View Article : Google Scholar : PubMed/NCBI
37	Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF and Shen HL: Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev. 15:29–32. 2014. View Article : Google Scholar : PubMed/NCBI
38	Štemberger C, Matušan-Ilijaš K, Avirović M, Bulat-Kardum L, Ivančić A, Jonjić N and Lučin K: Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma. Acta Histochem. 116:222–229. 2014. View Article : Google Scholar : PubMed/NCBI
39	Sun BS, You J, Li Y, Zhang ZF and Wang CL: Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin Med J (Engl). 126:1683–1688. 2013.PubMed/NCBI
40	Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL and Ma SC: The prognostic value of osteopontin expression in non-small cell lung cancer: A meta-analysis. J Mol Histol. 45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI